Bronchial endocrine tumor

Summary

Bronchial endocrine tumor (MONDO:0019963) is a cancer. A subtype of bronchial neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Phenotypes (HPO): 31

Clinical features

Signs & symptoms

Clinical features (HPO)

31 HPO clinical features (Orphanet curated; top 31 by frequency):

HPO ID	Term	Frequency
HP:0030445	Pulmonary carcinoid tumor	Obligate (100%)
HP:0001824	Weight loss	Frequent (30-79%)
HP:0002039	Anorexia	Frequent (30-79%)
HP:0002090	Pneumonia	Frequent (30-79%)
HP:0002094	Dyspnea	Frequent (30-79%)
HP:0002099	Asthma	Frequent (30-79%)
HP:0002105	Hemoptysis	Frequent (30-79%)
HP:0002730	Chronic noninfectious lymphadenopathy	Frequent (30-79%)
HP:0004396	Poor appetite	Frequent (30-79%)
HP:0006530	Abnormal pulmonary interstitial morphology	Frequent (30-79%)
HP:0030828	Wheezing	Frequent (30-79%)
HP:0031246	Nonproductive cough	Frequent (30-79%)
HP:0100749	Chest pain	Frequent (30-79%)
HP:4000007	Bronchoconstriction	Very rare (<1-4%)
HP:0000845	Elevated circulating growth hormone concentration	Very rare (<1-4%)
HP:0001005	Dermatological manifestations of systemic disorders	Very rare (<1-4%)
HP:0001399	Hepatic failure	Very rare (<1-4%)
HP:0001708	Right ventricular failure	Very rare (<1-4%)
HP:0001962	Palpitations	Very rare (<1-4%)
HP:0002240	Hepatomegaly	Very rare (<1-4%)
HP:0002615	Hypotension	Very rare (<1-4%)
HP:0003118	Increased circulating cortisol level	Very rare (<1-4%)
HP:0003144	Increased serum serotonin	Very rare (<1-4%)
HP:0003154	Increased circulating ACTH level	Very rare (<1-4%)
HP:0004385	Protracted diarrhea	Very rare (<1-4%)
HP:0005180	Tricuspid regurgitation	Very rare (<1-4%)
HP:0007380	Facial telangiectasia	Very rare (<1-4%)
HP:0012701	Bowel urgency	Very rare (<1-4%)
HP:0030149	Cardiogenic shock	Very rare (<1-4%)
HP:0030166	Night sweats	Very rare (<1-4%)
HP:0031566	Abnormal pulmonary valve cusp morphology	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	bronchial endocrine tumor
Mondo ID	MONDO:0019963
Orphanet	97287
GARD	0019360
Anatomy (UBERON)	UBERON:0002185
Is cancer (heuristic)	yes

Also known as: bronchial NET · bronchial neuroendocrine tumour · bronchus NET · bronchus neuroendocrine neoplasm · bronchus neuroendocrine tumor · bronchus neuroendocrine tumor, well differentiated, low or intermediate grade · bronchus neuroendocrine tumour · neuroendocrine neoplasm of bronchus

Disease family

This is a subtype of bronchial neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › bronchial disorder › bronchial neoplasm › bronchial endocrine tumor

Related subtypes (4): endobronchial lipoma, bronchus cancer, bronchus adenoma, endobronchial leiomyoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.